Skip to main content

Avalo Therapeutics, Inc. (AVTX)

NASDAQ: AVTX · IEX Real-Time Price · USD
2.25
-0.02 (-0.75%)
After-hours:Oct 15, 2021 4:39 PM EDT
2.27
-0.01 (-0.44%)
At close: Oct 15, 4:00 PM
Market Cap254.96M
Revenue (ttm)6.43M
Net Income (ttm)-76.89M
Shares Out95.47M
EPS (ttm)-0.87
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume369,552
Open2.33
Previous Close2.28
Day's Range2.23 - 2.33
52-Week Range1.98 - 4.50
Beta1.59
AnalystsStrong Buy
Price Target6.40 (+181.9%)
Est. Earnings DateNov 8, 2021

About AVTX

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. Its product pipeline includes AVTX-002, an Anti-LIGHT mAb targeting immune-inflammatory diseases, including acute respiratory distress syndrome and moderate-to-severe inflammatory bowel disease; and AVTX-007, an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases, including multiple myeloma and Still's dis...

IndustryBiotechnology
IPO DateOct 15, 2015
Employees30
Stock ExchangeNASDAQ
Ticker SymbolAVTX
Full Company Profile

Financial Performance

In 2020, AVTX's revenue was $6.70 million, a decrease of -0.77% compared to the previous year's $6.75 million. Losses were -$63.50 million, 295.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price forecast is 6.40, which is an increase of 181.94% from the latest price.

Price Target
$6.40
(181.94% upside)
Analyst Consensus: Strong Buy

News

Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit

WAYNE, Pa. and ROCKVILLE, Md., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

4 days ago - GlobeNewsWire

Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

1 month ago - GlobeNewsWire

Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of ...

2 months ago - GlobeNewsWire

Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn's Disease who had previously failed three or more lines of biologics therapi...

2 months ago - GlobeNewsWire

Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients

Cerecor Inc (NASDAQ: CERC) announced initial results from a Phase 1b proof-of-concept study evaluating CERC-002 in adult patients with moderate to severe Crohn's disease (CD). CERC-002 is an investigati...

2 months ago - Benzinga

Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

ROCKVILLE, Md. and CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of ...

2 months ago - GlobeNewsWire

Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and I...

Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders Cerecor completes divestiture of non-core neurolo...

3 months ago - GlobeNewsWire

7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...

Other symbols:CRSPHZNPJNJLLYSDGRTAK
4 months ago - InvestorPlace

Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of t...

5 months ago - GlobeNewsWire

Top Penny Stocks to Buy Moving in Premarket? Check These 3 Out

These 3 penny stocks made big moves in pre-market trading; are they worth it? The post Top Penny Stocks to Buy Moving in Premarket?

Other symbols:PHUNPLIN
5 months ago - PennyStocks

Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients

The FDA has granted Fast Track designation to Cerecor Inc's (NASDAQ: CERC) CERC-002 to treat hospitalized patients with COVID-19. CERC-002 is a first-in-class fully human monoclonal antibody targeting L...

5 months ago - Benzinga

A Small Biotech Stock That Has All The Right Ingredients for a Big 2021 Breakout

$230 million biopharmaceutical company Cerecor (CERC) may end up being the industry's biggest winner on Wall Street over the next six months. The post A Small Biotech Stock That Has All The Right Ingred...

5 months ago - InvestorPlace

Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002

Cerecor Inc's (NASDAQ: CERC) wholly-owned subsidiary, Aevi Genomic Medicine LLC, has entered into an expanded agreement with Kyowa Kirin Co Ltd (OTCMKTS: KYKOF) for exclusive worldwide rights to CERC-00...

6 months ago - Benzinga

Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002

ROCKVILLE, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare a...

6 months ago - GlobeNewsWire

Cerecor Reports 2020 Financial Results and Provides Business Updates

ROCKVILLE, Md. and CHESTERBROOK, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of tre...

7 months ago - GlobeNewsWire

Cerecor to Present at Upcoming Investor Conferences

ROCKVILLE, Md. and CHESTERBROOK, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of...

7 months ago - GlobeNewsWire

Cerecor Shares Are Trading Higher On Positive CERC-002 Efficacy Data In COVID-19 Study

Cerecor Inc (NASDAQ: CERC) shares gained premarket on the heels of final efficacy data, including 60-day mortality from the Phase 2 trial evaluating CERC-002 in hospitalized patients with COVID-19 assoc...

7 months ago - Benzinga

Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II

ROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and or...

8 months ago - GlobeNewsWire

Cerecor Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceed...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor”; NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializat...

8 months ago - GlobeNewsWire

Cerecor Inc. Announces Closing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

9 months ago - GlobeNewsWire

Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

9 months ago - GlobeNewsWire

Cerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

9 months ago - GlobeNewsWire

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still's Di...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

9 months ago - GlobeNewsWire

Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refra...

Initial data anticipated in the first quarter of 2021 Initial data anticipated in the first quarter of 2021

10 months ago - GlobeNewsWire

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Def...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

10 months ago - GlobeNewsWire